Drug Profile
Research programme: selective progesterone receptor modulators - Evestra
Alternative Names: Antiprogestins - Evestra; EVE-104; Mesoprogestins - EvestraLatest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Evestra
- Developer Evestra; Northwestern University
- Class Steroids
- Mechanism of Action Selective progesterone receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Endometriosis; Pregnancy; Uterine leiomyoma
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Endometriosis in USA
- 28 Feb 2018 No recent reports of development identified for preclinical development in Uterine-leiomyoma in USA
- 28 Feb 2018 No recent reports of development identified for research development in Breast-cancer in USA